Renalytix (RENX) & Panoply (TPX): 2 AIM AI stocks to buy

3 min read | October 01, 2021 07:40 PM AEST | By Nidhi Gupta

Highlights 

  • Renalytix and the US-based Mount Sinai Health System announced the scale-up implementation of the former’s KidneyIntelX platform.
  • The Panoply Holdings announced a final dividend of 0.4 pence per share for the year ended 31 March 2021.

Artificial intelligence (AI), including machine learning and deep learning, leverages computers to conduct tasks that would otherwise require human intelligence. It enables machines to learn, adjust to new inputs and perform tasks similar to humans. AI stocks have been garnering tremendous attention from investors.

Many technology firms use AI to make their business operations more robust through high-profile applications, including robotic process automation, robotics, and virtual assistants. Some companies also gain from AI through the sales of software, hardware, services, and expertise required for the proper functioning of the technology. Its plethora of applications across a number of sectors is further boosting investor interest in the technology. The rise in the number of publicly-listed AI firms underlines the growing trend and rising investor interest in the field.

Renalytix (RENX) & The Panoply (TPX): One year return & market cap

(Data source: EODHD/Others)

Let us review the investment potential in two artificial intelligence (AI) stocks.

Renalytix Plc (LON: RENX)

Renalytix is an artificial intelligence-powered provider of in vitro diagnostics. The company is focused on optimising clinical management of kidney disorders and driving improved patient outcomes. Recently, Renalytix and the US-based Mount Sinai Health System announced the scale-up implementation of the former’s KidneyIntelX platform across primary health care and specialty clinic networks for patients suffering from diabetic kidney disease (DKD).

Renalytix recorded service revenue of $0.6 million and testing revenue of $0.1 million for the quarter ended 31 March 2021.

Currently, Renalytix shares trade flat at GBX 725.00 as of 9:54 AM GMT+1 on 1 October 2021.

Renalytix’s shares returned 73.44% in the last one year to shareholders, and the market cap stood at £523.75 million.

The Panoply Holdings Plc (LON: TPX)

The Panoply Holdings is a digitally native technology and consulting services provider. It is engaged in offering robotics, automation, chatbots and artificial intelligence (AI) solutions. During the first five months of trading in H1 2022, The Panoply Holdings secured new contracts worth £50 million compared to £18 million in the same period in the previous year, representing a 177% year-on-year increase in order intake. Its new contracts encompass £10 million worth of contract wins from the utility sector.

Currently, The Panoply Holdings shares traded lower by 0.98 per cent at GBX 252.50 as of 9:52 AM GMT+1 on 1 October 2021. The Panoply Holdings’ shares returned 129.73% in the last one year to shareholders, and the market cap stood at £216.25 million.

The Panoply Holdings revenues rose by 62% year-on-year to £51.1 million for the year ended 31 March 2021 compared to £31.5 million in the previous year. In July 2021, it acquired Nudge Digital Limited, a digital services provider to the pharma and health sectors.

The Panoply Holdings announced a final dividend of 0.4 pence per share for the year ended 31 March 2021.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.